37 completed, 4 terminated, 3 unknown, 2 not yet recruiting. 50 Phase 2, 7 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 50 | Completed 37, Terminated 4, Unknown 3, Not yet recruiting 2, Recruiting 2, Withdrawn 2 |
| Phase 3 | 7 | Completed 6, Not yet recruiting 1 |
| Phase 1 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
Follow Sitagliptin: new trials by email Literature Review of Sitagliptin trials Research Report on Sitagliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas Sitagliptin - Glioblastoma, Brain Tumor | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 48 | 2026-03-16 | 2026-11-17 |
| High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD Sitagliptin, Bortezomib, Cyclophosphamide - Bone Marrow Transplant Complications, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Indiana University | 2023-11-01 | 2024-04-29 | |
| Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH DA-1241, Sitagliptin, DA-1241 Placebo - NON-ALCOHOLIC STEATOHEPATITIS | Phase 2 | Completed | NeuroBo Pharmaceuticals Inc. | 109 | 2023-09-14 | 2024-11-14 |
| Effects of Sitagliptin in Relatives of T1D Patients Sitagliptin, Professional CGM - Type 1 Diabetes | Phase 2 / Phase 3 | Not yet recruiting | University of Milan | 70 | 2023-07-01 | 2023-05-10 |
| Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study Metformin Extended Release Oral Tablet, Sitagliptin - Type 1 Diabetes, Monogenic Diabetes | Phase 2 / Phase 3 | Completed | Joslin Diabetes Center | 3 | 2021-08-26 | 2025-02-24 |
| The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia Sitagliptin, Danazol - Immune Thrombocytopenia, Blood Coagulation Disorders | Phase 2 | Unknown | Peking University People's Hospital | 120 | 2021-06-01 | 2022-04-29 |
| Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients placebo, metformin, Sitagliptin - Polycystic Ovary Syndrome, Infertility | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 80 | 2020-01-10 | 2021-03-22 |
| Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) Evogliptin, Sitagliptin, Placebo Evogliptin - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Eurofarma Laboratorios S.A. | 146 | 2017-08-08 | 2018-08-14 |
| Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Sitagliptin - Graft vs Host Disease, Hematopoietic Stem Cell Transplantation | Phase 2 | Completed | Sherif S. Farag | 37 | 2016-02-03 | 2021-01-22 |
| Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity Sitagliptin, Placebo - Atherosclerosis, Inflammation | Phase 2 | Completed | University of Southern California | 21 | 2016-01-01 | 2019-07-17 |
| Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes LIK066, Sitagliptin, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2015-11-01 | 2014-04-03 | |
| Sitagliptin for Reducing Inflammation and Immune Activation Sitagliptin, Placebo for sitagliptin - HIV-1 Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 90 | 2015-09-01 | 2018-06-18 |
| Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes Sitagliptin, Placebo - Gastroparesis, Diabetes Mellitus | Phase 2 | Completed | Royal Adelaide Hospital | 14 | 2015-07-01 | 2017-07-07 |
| A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients GSK2330672, Placebo, Sitagliptin - Diabetes Mellitus, Type 2 | Phase 2 | Completed | GlaxoSmithKline | 70 | 2014-08-27 | 2017-11-06 |
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. Sitagliptin, Gliclazide, Sitagliptin matched placebo - Psoriasis, Type 2 Diabetes Mellitus | Phase 2 | Completed | University College Dublin | 20 | 2014-04-01 | 2020-05-14 |
| A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus LY2409021, Sitagliptin, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Eli Lilly and Company | 174 | 2014-04-01 | 2019-10-09 |
| Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease Sitagliptin, Placebo - Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | University of California, San Diego | 50 | 2014-01-01 | 2016-10-20 |
| Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes Sitagliptin, Exercise - Diabetes Mellitus Type 1 | Phase 2 | Completed | University Hospital, Basel, Switzerland | 24 | 2013-11-01 | 2017-07-27 |
Showing 20 of 50. Sign in to see all of them.
Diabetes Mellitus, Type 2 (22) · Diabetes Mellitus (8) · Diabetes Mellitus, Type 1 (6) · Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Glucose Intolerance (2) · Inflammation (2) · Insulin Resistance (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma, Non-Hodgkin (2) · Myelodysplastic Syndromes (2) · Non-alcoholic Fatty Liver Disease (2) · Anemia, Refractory, with Excess of Blasts (1) · Atherosclerosis (1) · Blood Coagulation Disorders (1)
Novartis Pharmaceuticals (4) · Boehringer Ingelheim (3) · GlaxoSmithKline (3) · Eli Lilly and Company (2) · Indiana University (2) · Merck Sharp & Dohme LLC (2) · Sherif S. Farag (2) · Takeda (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Case Comprehensive Cancer Center (1) · Eurofarma Laboratorios S.A. (1) · European Foundation for the Study of Diabetes (1) · Gilead Sciences (1) · Johns Hopkins University (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)
United States (27) · Canada (7) · Germany (7) · Italy (5) · Romania (5) · India (4) · Mexico (4) · Poland (4) · Puerto Rico (4) · Russia (4) · Taiwan (4) · Argentina (3) · Austria (3) · China (3) · Czechia (3)
Sherif Farag, MD, PhD (2) · Alin Stirban, MD (1) · Balow James, MD (1) · Bernard Zinman, MD (1) · Brian Kirby, MBBChBAOMD (1) · Brian Roberts, MD (1) · Dariush Elahi, PhD (1) · David Peereboom, MD (1) · Fred Sattler, MD (1) · Gary Lewis, MD (1)
PMID 24432999, PMID 24699248, PMID 10752702, PMID 19073764, PMID 19689275, PMID 21636800, PMID 22492586, PMID 22548646, PMID 22632452, PMID 22761275, PMID 23264399, PMID 23270493, PMID 23294774, PMID 23780460, PMID 23940010, PMID 24186878, PMID 24550217, PMID 24584549, PMID 24762094, PMID 25229125, PMID 25495067, PMID 25912221, PMID 26362564, PMID 26404926, PMID 26691396, PMID 27087519, PMID 27161178, PMID 27612849, PMID 28191913, PMID 28755389, PMID 28929327, PMID 30707388, PMID 30895467, PMID 31180194, PMID 31442575, PMID 31890041, PMID 32720198, PMID 33406328, PMID 33475138, PMID 3517648, PMID 35472672, PMID 36318027, PMID 36894938
2008 (1), R01HL112669 (1), UM1AI068636 (1)